Dopamine Receptor Subtypes in the Native Human Heart

Overview

Journal Heart Vessels

Specialty Cardiology & Vascular Diseases

Date 2010 Aug 3

PMID 20676967

Citations 19

Authors

Carlo Cavallotti

Massimo Mancone

Paolo Bruzzone

Maurizio Sabbatini

Fiorenzo Mignini

Affiliations

Soon will be listed here.

Abstract

The present study first time detected D1-D5 dopamine receptor subtypes in the native human heart simultaneously, found presence of D1, D2, D4, and D5 in cardiac tissues, and revealed distribution features of dopamine receptor subtypes in the epicardium, myocardium, and endocardium. Samples from four native hearts coming from young brain-dead donors, which for technical reason were not used for transplants, were studied. Dopamine receptors were revealed by immunochemistry technique and immunoblot analysis. Morphometrical quantification of the density of each receptor subtype was performed by an image analyzer. Our results demonstrate that only four subtypes of dopamine receptors can be found in cardiac tissues: D1, D2, D4, and D5. These dopamine receptors have been detected in endocardium, myocardium, and epicardium. D1 receptors were stored primarily in the epicardial layer. Dopamine receptors are distributed in the wall of both atria and ventricles, and its transmural gradient can be described in the wall of the human heart. Sections of atria and ventricles exposed to antidopamine receptor antibodies showed fluorescent-positive reaction in the epicardium, myocardium and endocardium. D4 receptor immune reactivity was remarkably less intense than D2 receptor immune reactivity. All the subtypes of dopamine receptors are in close relationships with all cardiac structures. Our findings provide a favorable basis for researching the role of dopamine receptors in controlling functions of the human heart and in the pathogenesis of cardiovascular diseases.

Citing Articles

Dopamine receptors and organ fibrosis.

Liao Z, Tang X, Yang B, Yang J Biochem Biophys Rep. 2025; 41:101910.

PMID: 39867679 PMC: 11761258. DOI: 10.1016/j.bbrep.2024.101910.

Contractile effects of stimulation of D-dopamine receptors in the isolated human atrium.

Gergs U, Pham T, Rayo Abella L, Hesse C, Grundig P, Dhein S Naunyn Schmiedebergs Arch Pharmacol. 2024; 398(2):1497-1508.

PMID: 39102031 PMC: 11825631. DOI: 10.1007/s00210-024-03340-z.

Initial characterization of a transgenic mouse with overexpression of the human D-dopamine receptor in the heart.

Rayo Abella L, Jacob H, Hesse C, Hofmann B, Schneider S, Schindler L Naunyn Schmiedebergs Arch Pharmacol. 2024; 397(7):4939-4959.

PMID: 38177456 PMC: 11166794. DOI: 10.1007/s00210-023-02901-y.

Anti-Inflammatory Effects of Peripheral Dopamine.

Moore S, de Castro P, Yaqub D, Jose P, Armando I Int J Mol Sci. 2023; 24(18).

PMID: 37762126 PMC: 10530375. DOI: 10.3390/ijms241813816.

Role of Dopamine in the Heart in Health and Disease.

Neumann J, Hofmann B, Dhein S, Gergs U Int J Mol Sci. 2023; 24(5).

PMID: 36902474 PMC: 10003060. DOI: 10.3390/ijms24055042.

References

Giros B, Sokoloff P, Martres M, Riou J, Emorine L, Schwartz J . Alternative splicing directs the expression of two D2 dopamine receptor isoforms. Nature. 1989; 342(6252):923-6. DOI: 10.1038/342923a0. View

Wolfe S, Morris S . Dopamine D2 receptor isoforms expressed in AtT20 cells differentially couple to G proteins to acutely inhibit high voltage-activated calcium channels. J Neurochem. 1999; 73(6):2375-82. DOI: 10.1046/j.1471-4159.1999.0732375.x. View

Bai C, Liu X, Liu W, Ma D . Regional expression of the hypoxia-inducible factor (HIF) system and association with cardiomyocyte cell cycle re-entry after myocardial infarction in rats. Heart Vessels. 2008; 23(3):193-200. DOI: 10.1007/s00380-007-1029-2. View

Gingrich J, Caron M . Recent advances in the molecular biology of dopamine receptors. Annu Rev Neurosci. 1993; 16:299-321. DOI: 10.1146/annurev.ne.16.030193.001503. View

Cavallotti C, Nuti F, Bruzzone P, Mancone M . Age-related changes in dopamine D2 receptors in rat heart and coronary vessels. Clin Exp Pharmacol Physiol. 2002; 29(5-6):412-8. DOI: 10.1046/j.1440-1681.2002.03677.x. View

Takeuchi Y, Fukunaga K . Differential subcellular localization of two dopamine D2 receptor isoforms in transfected NG108-15 cells. J Neurochem. 2003; 85(4):1064-74. DOI: 10.1046/j.1471-4159.2003.01763.x. View

Sherlock M, Toogood A, Steeds R . Dopamine agonist therapy for hyperprolactinaemia and cardiac valve dysfunction; a lot done but much more to do. Heart. 2009; 95(7):522-3. DOI: 10.1136/hrt.2008.163345. View

Goldberg L . Cardiovascular and renal actions of dopamine: potential clinical applications. Pharmacol Rev. 1972; 24(1):1-29. View

Sibley D, Monsma Jr F . Molecular biology of dopamine receptors. Trends Pharmacol Sci. 1992; 13(2):61-9. DOI: 10.1016/0165-6147(92)90025-2. View

10.

Gildea J . Dopamine and angiotensin as renal counterregulatory systems controlling sodium balance. Curr Opin Nephrol Hypertens. 2008; 18(1):28-32. PMC: 2847451. DOI: 10.1097/MNH.0b013e32831a9e0b. View

11.

Moens A, Claeys M, Timmermans J, Vrints C . Myocardial ischemia/reperfusion-injury, a clinical view on a complex pathophysiological process. Int J Cardiol. 2005; 100(2):179-90. DOI: 10.1016/j.ijcard.2004.04.013. View

12.

Shin S, Lee J, Min B, Han Lee Y . The translation inhibitor anisomycin induces Elk-1-mediated transcriptional activation of egr-1 through multiple mitogen-activated protein kinase pathways. Exp Mol Med. 2007; 38(6):677-85. DOI: 10.1038/emm.2006.80. View

13.

Goldberg L, KOHLI J . Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system?. Commun Psychopharmacol. 1979; 3(6):447-56. View

14.

Li H, Han L, Jiang C, Li H, Zhao Y, Gao J . Effect of dopamine receptor 1 on apoptosis of cultured neonatal rat cardiomyocytes in simulated ischaemia/reperfusion. Basic Clin Pharmacol Toxicol. 2008; 102(3):329-36. DOI: 10.1111/j.1742-7843.2007.00177.x. View

15.

Yamamoto T, Shirayama T, Takahashi T, Matsubara H . Altered expression of Na+ transporters at the mRNA level in rat normal and hypertrophic myocardium. Heart Vessels. 2009; 24(1):54-62. DOI: 10.1007/s00380-008-1071-8. View

16.

Gero D, Modis K, Nagy N, Szoleczky P, Dori Toth Z, Dorman G . Oxidant-induced cardiomyocyte injury: identification of the cytoprotective effect of a dopamine 1 receptor agonist using a cell-based high-throughput assay. Int J Mol Med. 2007; 20(5):749-61. View

17.

Dal Toso R, Sommer B, Ewert M, Herb A, Pritchett D, Bach A . The dopamine D2 receptor: two molecular forms generated by alternative splicing. EMBO J. 1989; 8(13):4025-34. PMC: 401577. DOI: 10.1002/j.1460-2075.1989.tb08585.x. View

18.

Jose P, Eisner G, Felder R . Renal dopamine and sodium homeostasis. Curr Hypertens Rep. 2000; 2(2):174-83. DOI: 10.1007/s11906-000-0079-y. View

19.

Remme W . Dopaminergic agents in heart failure: rebirth of an old concept. Cardiovasc Drugs Ther. 2001; 15(2):107-9. DOI: 10.1023/a:1011162510450. View

20.

Ozono R, OConnell D, Vaughan C, Botkin S, Walk S, Felder R . Expression of the subtype 1A dopamine receptor in the rat heart. Hypertension. 1996; 27(3 Pt 2):693-703. DOI: 10.1161/01.hyp.27.3.693. View